COPD patients and clinicians see clear promise in breath-based remote monitoring: a new LUMC study highlights how RespiQ’s non-invasive breath analysis could fit in an effort to enable earlier detection of flare-ups, supporting proactive care through technology co-created with patients and healthcare professionals.

RespiQ uses AI and advanced spectroscopy to detect disease-related molecules in human breath at parts-per-billion levels. Through tight collaboration between experimental and data science teams, we’re overcoming long-standing challenges in breath biomarker detection and moving toward a future of reliable, continuous health monitoring.